Clinical Trials Directory

Trials / Unknown

UnknownNCT05911516

Pennisetum Purpureum in Sarcopenia Patients

Effects of Pennisetum Purpureum Health Food Supplementation on Muscle Mass and Muscle Strength

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Taipei Medical University · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to investigate the effects of Pennisetum purpureum health food supplementation on muscle mass and muscle strength.

Detailed description

All participants performed anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey before supplementation. Participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference. The definition of insufficient muscle mass was based on the Asian working group for sarcopenia (AWGS) that skeletal muscle mass in extremities by dual-energy X-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women is a necessary condition, and one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than12 seconds. The anthropometric measurements (body height, body weight, BMI, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey, were collected after 8 weeks and 12 weeks of supplementation.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPennisetum purpureum300mg Participants received 900mg of Pennisetum purpureum orally daily for 12 weeks
DIETARY_SUPPLEMENTPlaceboPlacebo

Timeline

Start date
2023-06-01
Primary completion
2024-03-01
Completion
2024-03-01
First posted
2023-06-22
Last updated
2023-12-19

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT05911516. Inclusion in this directory is not an endorsement.